The Canadian government has granted permission to a startup for the export of psychedelic substances to Australia for medical use. Optimi Health Corp. has been given the responsibility to export pills infused with psilocybin, an extract from magic mushrooms, and MDMA, with the authorization of the health department.
The growing demand is not limited to the local magic mushrooms Ontario. Other countries are learning from Canada and are beginning to investigate and allow the use of these serotogenic compounds for medicinal purposes.
Feel secure when you buy psychedelics online in Canada and unleash your inherent potential through trustworthy sources.
[toc]Main Takeaways:
- Optimi Health, a Vancouver-based startup, has been given a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in the treatment of chronic depression.
- The treatment comprises three sessions over five to eight weeks, with each session lasting about eight hours.
The Rise of Psilocybin Capsules in Canada
Optimi, a small company based in Vancouver, aims to use its certification to enlarge the pharmaceutical market for psychedelic drugs and gain an early market entry advantage.
Seven firms have exported psilocybin, MDMA, or both, but only for clinical trial purposes. A spokesperson from Canada’s health department was unable to confirm if these exports were for regular patient use and chose not to reveal the companies due to security considerations.
This accomplishment places Optimi among a limited group of global suppliers, with the current market favoring clinical over recreational use.
What’s in the Pill?
Although the company has not revealed the specific type of mushroom used in the pill, they do work with a range of strains including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town is home to approximately 3,000 residents and can be found a three-hour drive east of Vancouver.
The Connection Between Australia and Psychedelic Mushrooms
It’s projected that 1 in 5 Australians between the ages of 16 and 85 may experience mental illness. PTSD (post-traumatic stress disorder) is likely to affect around 11% of Australians at some point in their lifetime, and anxiety disorders are prevalent in 17% of the population.
A myriad of methods exist for treating mental conditions, but effectiveness varies among individuals. Patients who don’t respond to certain treatments may struggle to find an approach that works for them, thereby increasing their susceptibility.
The Methodology Unveiled
Australia has been a leader in the use of psilocybin, allowing certified psychiatrists to employ this regulated substance in treating PTSD and depression resistant to traditional treatments.
In an unexpected move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic use. The TGA declared these substances to be safe when used in a medically controlled setting for patients battling severe mental disorders.
This shift has revolutionized the perspective of numerous mental health professionals and researchers. The use of these substances will be tightly regulated; it’s more than just taking a pill and walking away.
The treatment strategy typically involves three sessions spanning five to eight weeks. Each session lasts about eight hours, with the therapist present throughout the entire duration.
Canada’s Role in Psilocybin Research
Canada has emerged as a key player in psilocybin research, contributing significantly to our understanding of this compound. Health Canada, along with various institutions, is spearheading the investigation into psilocybin’s therapeutic potential for treating diverse mental health disorders.
Research institutions no longer need to label these substances as illegal or rely on unlicensed dispensaries or mushroom shops. The government now permits certain institutions to grow mushrooms for research purposes.
The newfound access to substances once deemed harmful enables researchers to deepen their understanding of potential benefits for many individuals.
A Cyclic Patterns
The potential of this field was initially identified in the 1950s as a means to address mental health problems and substance misuse, including alcohol addiction. This pioneering research was carried out at the Saskatchewan Mental Hospital in Weyburn by English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer. Significant progress was made under the leadership of then-premier Tommy Douglas, who allowed medical professionals significant freedom to explore their theories.
Dr. Osmond and Dr. Hoffer began their investigations with LSD, mescaline, and peyote, as potential alternatives to harsh procedures like electroshock and lobotomy. Their research took unexpected turns, leading them to propose that doctors, nurses, and auxiliary staff experiment with these substances.
Research by Canadian Health Institutes
The Canadian Institutes of Health Research, through the Institute of Neurosciences, Mental Health and Addiction, is funding three clinical trials. These trials aim to investigate the therapeutic efficacy and safety of psilocybin-assisted psychotherapy in the following manner:
| Project Type | Study Focus | Research Institution | Principal Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in end-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Understanding the mechanisms behind psilocybin psychotherapy for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a deeper understanding of the advantages of controlled substances. This initiative is part of the Canadian Drugs and Substances Strategy (CDSS) launched by the Government of Canada.
Further Psychedelic Research
Psychiatrists in Vancouver have launched a phase III clinical trial of MDMA, also known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The treatment protocol includes three eight-hour sessions with MDMA, each spaced a month apart, and nine 90-minute sessions without the drug. Researchers consider this trial to be of historical significance as it is the first clinical examination of an illegal
This is the first FDA-approved study on a psychedelic substance in over four decades.
Introduction to Psilocybin
Psilocybin, a naturally occurring psychedelic compound present in certain species of mushrooms, metabolizes into psilocin upon consumption. The psilocin activates the serotonin 5-HT2a receptors positioned on the cortical pyramidal cells in the brain, which are the primary processing locations.
Local authorities are studying the substance for its potential benefits in dealing with depression, anxiety, addiction, and distress associated with end-of-life, through promoting introspection and spiritual enlightenment.
Why is Psilocybin Effective in Treating Depression, PTSD, and More?
The active component targets several areas in the brain, making it useful for diverse mental conditions. A number of patients in Canada and Australia have already undergone this therapy and the reported results are promising, with minor side effects such as temporary anxiety or increased blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: This compound partially engages the serotonin receptors, especially the 5-HT2A subtype, which plays a key role in emotional processing and mood control.
- Modulation of Default Mode Network (DMN): It lowers activity in the DMN, promoting introspection, minimizing rigid thinking patterns, and fostering emotional adaptability.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the compound result from its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depressive cases, individuals usually show a reduced response to emotional stimuli. The compound enhances the response to positive emotional stimuli in the right amygdala and decreases or normalizes the response to negative or neutral emotional stimuli.
Impacts on Psychology and Emotion:
- Creation of Positive Mood States: It promotes sensations of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience may help individuals to safely address and process deeply ingrained emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Realizations: Research from Johns Hopkins University and Imperial College London suggests that it can promote long-lasting positive changes, such as better overall well-being, increased life satisfaction, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Shop?
Interested in how the substance might benefit your mental health? Explore your local magic mushroom store to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, fosters creative thinking, and enhances focus and productivity |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Supports improved well-being and enhances quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Promotes clarity, creativity, and concentration. Contains a powerful blend of clinical-strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy enhancements |
Worldwide Acknowledgement of Psilocybin
Canada is not the only country recognizing the benefits of magic mushrooms for mental health issues. Nations like Australia are also embracing the use of these hallucinogens to treat conditions such as depression and PTSD. They are procuring high-quality psychedelic capsules from trustworthy sources. Under proper guidance, patients can greatly improve their quality of life. Sero Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Both psilocybin and MDMA have therapeutic potential to enhance mental well-being. Psilocybin interacts with serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA promotes empathy and is beneficial in PTSD treatment. It demonstrates potential in improving emotional processing and
Despite its classification as a controlled substance, this treatment has shown promising therapeutic outcomes.
Is this treatment option available to all Australians?
Not necessarily. In Australia, potential users must first undergo an evaluation to assess their suitability for utilizing the substance. This assessment takes into account factors such as pre-existing heart conditions and a history of psychosis. Only patients who have not seen improvements with conventional treatments for conditions like depression, anxiety, or PTSD are considered eligible for this treatment.
What is the impact of Canada exporting mushrooms?
Canada is setting itself up to become a major player in the psychedelics market, mirroring its approach with cannabis. This could encourage more companies to produce high-quality products. As a result, Canada could potentially lead the global hallucinogen market, strengthening its economy, and providing other countries with access to these treatments. This also helps to prevent countries from resorting to illegal dispensaries or suppliers for their hallucinogen needs, ensuring safety.
Interesting Articles You Might Want to Read:
